trending Market Intelligence /marketintelligence/en/news-insights/trending/yuwjq1z-rnujgxekdsfaua2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US appeals court denies Hikma unit's rehearing request in Vanda patent suit

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US appeals court denies Hikma unit's rehearing request in Vanda patent suit

The U.S. Court of Appeals for the Federal Circuit denied West-Ward Pharmaceutical Corp.'s petitions challenging the outcome of a patent infringement suit.

The subsidiary of London-based Hikma Pharmaceuticals PLC was seeking a rehearing on the court's earlier decision to uphold the U.S. District Court for the District of Delaware's ruling that said it had infringed on U.S. patent number 8,586,610 covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt.

Washington, D.C.-based Vanda said the patent will expire Nov. 2, 2027.